Studying Health Outcomes After Treatment in Patients With Retinoblastoma
This trial studies health outcomes after treatment in patients with retinoblastoma. Gathering health information over time from patients and family members through vision assessments, samples of tissue and saliva, and questionnaires may help doctors learn more about what causes retinoblastoma, identify long-term health outcomes for patients with retinoblastoma, and find out which therapies may be the best for treating retinoblastoma
- Unilateral or bilateral intraocular retinoblastoma
- Diagnosis between the ages of 0 - 17.99 years
- Diagnosis on or after January 1, 2008
- No exclusions based on primary or secondary treatment modalities
Retrospective group patients must be ≥ 6 months post end of treatment at study entry
- For those already at this timepoint, they are now eligible
- For those in treatment, or otherwise not yet at this timepoint, they are eligible once at they are ≥ 6 months post end of treatment
- Prospective group patients must not have begun treatment
Patients with diminished capacity will not be enrolled.
Language: Patients must be able to communicate in English, French, or Spanish
Sibling Cohort: One sibling, not affected by retinoblastoma will be enrolled, preference for the sibling closest in age to the RB patient.
Regulatory Requirements: All patients and/or their parents or legal guardians must sign a written informed consent. All institutional, FDA, and NCI requirements for human studies must be met.
PROCEDURE: Biospecimen collection, OTHER: Vision assessment, OTHER: Questionnaire administration, OTHER: Quality of life assessment, OTHER: Laboratory Biomarker Analysis
Retinoblastoma, Cancer Survivor, Biological Sibling, Intraocular Retinoblastoma, Unilateral Retinoblastoma